ECSP13013011A - Triazolopiridinas - Google Patents

Triazolopiridinas

Info

Publication number
ECSP13013011A
ECSP13013011A ECSP13013011A ECSP13013011A EC SP13013011 A ECSP13013011 A EC SP13013011A EC SP13013011 A ECSP13013011 A EC SP13013011A EC SP13013011 A ECSP13013011 A EC SP13013011A
Authority
EC
Ecuador
Prior art keywords
compounds
preparing
triazolopiridins
prophylaxis
disease
Prior art date
Application number
Other languages
English (en)
Inventor
Hans Briem
Dirk Kosemund
Volker Schulze
Philip Lienau
Hartmut Schirok
Antje Margret Wengner
Detlef Stöckigt
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of ECSP13013011A publication Critical patent/ECSP13013011A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compuestos de triazolopiridina de la fórmula general (I): donde R1, R2, R3, R4 y R5 tienen los valores que se definen en la descripción y en las reivindicaciones. Métodos para preparar dichos compuestos. Composiciones y combinaciones farmacéuticas que comprenden dichos compuestos. Uso de dichos compuestos para preparar una composición farmacéutica para el tratamiento o la profilaxis de una enfermedad. Compuestos intermediarios útiles para preparar dichos compuestos.
ECSP13013011 2011-04-21 2013-11-05 Triazolopiridinas ECSP13013011A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11163342 2011-04-21
EP11167872 2011-05-27

Publications (1)

Publication Number Publication Date
ECSP13013011A true ECSP13013011A (es) 2013-12-31

Family

ID=46124297

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13013011 ECSP13013011A (es) 2011-04-21 2013-11-05 Triazolopiridinas

Country Status (39)

Country Link
US (1) US20140120087A1 (es)
EP (1) EP2699575B1 (es)
JP (1) JP5989091B2 (es)
KR (1) KR20140025470A (es)
CN (1) CN103608350B (es)
AP (1) AP3491A (es)
AR (1) AR086191A1 (es)
AU (1) AU2012244859B2 (es)
CA (1) CA2833657A1 (es)
CL (1) CL2013003044A1 (es)
CO (1) CO6801751A2 (es)
CR (1) CR20130539A (es)
CY (1) CY1116439T1 (es)
DK (1) DK2699575T3 (es)
DO (1) DOP2013000244A (es)
EA (1) EA023766B1 (es)
EC (1) ECSP13013011A (es)
ES (1) ES2539265T3 (es)
GT (1) GT201300254A (es)
HR (1) HRP20150517T1 (es)
HU (1) HUE025496T2 (es)
IL (1) IL228704A0 (es)
JO (1) JO3040B1 (es)
MA (1) MA35049B1 (es)
ME (1) ME02143B (es)
MX (1) MX348783B (es)
MY (1) MY164939A (es)
PE (1) PE20141351A1 (es)
PH (1) PH12013502169A1 (es)
PL (1) PL2699575T3 (es)
PT (1) PT2699575E (es)
RS (1) RS54044B1 (es)
SA (1) SA112330466B1 (es)
SG (1) SG194003A1 (es)
SI (1) SI2699575T1 (es)
TW (1) TWI558703B (es)
UY (1) UY34034A (es)
WO (1) WO2012143329A1 (es)
ZA (1) ZA201308707B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA111841C2 (uk) 2011-04-21 2016-06-24 Гіліад Сайєнсіз, Інк. Сполуки бензотіазолу та їх фармацевтичне застосування
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
WO2013103738A1 (en) 2012-01-04 2013-07-11 Gilead Sciences, Inc. Napthalene acetic acid derivatives against hiv infection
US9376392B2 (en) 2012-01-04 2016-06-28 Gilead Sciences, Inc. 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS
JP6166289B2 (ja) 2012-03-14 2017-07-19 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換イミダゾピリダジン
BR112015000308A2 (pt) 2012-07-10 2017-06-27 Bayer Pharma AG método para preparo de triazolopiridinas substituídas
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
WO2014020041A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
CA2914521A1 (en) * 2013-06-07 2014-12-11 Bayer Pharma Aktiengesellschaft Substituted triazolopyridines having activity as mps-1 inhibitors
CA2914516A1 (en) * 2013-06-07 2014-12-11 Bayer Pharma Aktiengesellschaft Substituted triazolopyridines
CN105246891A (zh) * 2013-06-10 2016-01-13 拜耳制药股份公司 用于治疗癌症的新化合物
EP3007692A1 (en) * 2013-06-11 2016-04-20 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor
PE20160156A1 (es) 2013-06-11 2016-04-20 Bayer Pharma AG Derivados de prodroga de triazolpiridinas sustituidas
EP2860177A3 (en) 2013-09-20 2015-06-10 Bayer Intellectual Property GmbH Synthesis of functionalized arenes
EP3283642B1 (en) 2015-04-17 2023-10-11 Netherlands Translational Research Center Holding B.V. Prognostic biomarkers for ttk inhibitor chemotherapy
WO2018166493A1 (zh) * 2017-03-16 2018-09-20 江苏恒瑞医药股份有限公司 杂芳基并[4，3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用
NZ780966A (en) 2019-04-18 2026-02-27 Univ Johns Hopkins Substituted 2-amino-pyrazolyl-[1,2,4]triazolo[1,5a] pyridine derivatives and use thereof
JP2022539208A (ja) 2019-07-03 2022-09-07 スミトモ ファーマ オンコロジー， インコーポレイテッド チロシンキナーゼ非受容体１（ｔｎｋ１）阻害剤およびその使用
IL301817A (en) 2020-10-13 2023-06-01 Univ Johns Hopkins Modified 4-([4,2,1]triazolo[5,1-a]pyridin-6-yl)thiophene-2-carboxamide histories and their use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
RU2007109778A (ru) 2004-08-17 2008-09-27 Галдерма Ресерч Энд Девелопмент, С.Н.С. (Fr) Новые биароматические соединения, которые активируют рецепторы типа ppar, и их применение в косметических и фармацевтических композициях
ES2549862T3 (es) * 2006-08-30 2015-11-02 Cellzome Limited Derivados de triazol como inhibidores de quinasa
EP2178868A1 (en) * 2007-07-18 2010-04-28 Novartis Ag Bicyclic heteroaryl compounds and their use as kinase inhibitors
MX2010002115A (es) 2007-08-23 2010-06-01 Aztrazeneca Ab 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos .proliferativos.
MX2010002312A (es) 2007-08-31 2010-03-18 Merck Serono Sa Compuestos de triazolopiridina y su uso como inhibidores de cinasa reguladora de señal de apoptosis.
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
EP2222674B8 (en) * 2007-11-27 2016-01-06 Cellzome Limited Amino triazoles as pi3k inhibitors
CN102317288A (zh) * 2009-02-13 2012-01-11 佛维雅制药公司 作为激酶抑制剂的[1,2,4]三唑并[1,5-a]吡啶
ES2547328T3 (es) 2009-04-29 2015-10-05 Bayer Intellectual Property Gmbh Imidazoquinoxalinas sustituidas
JP5728683B2 (ja) 2009-09-04 2015-06-03 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ チロシンスレオニンキナーゼ阻害剤としての置換アミノキノキサリン
EP2343297A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
UY33452A (es) * 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas

Also Published As

Publication number Publication date
RS54044B1 (sr) 2015-10-30
NZ616456A (en) 2015-09-25
JP5989091B2 (ja) 2016-09-07
SA112330466B1 (ar) 2015-09-28
UY34034A (es) 2012-11-30
GT201300254A (es) 2015-09-01
TW201245194A (en) 2012-11-16
CA2833657A1 (en) 2012-10-26
PE20141351A1 (es) 2014-11-01
CR20130539A (es) 2013-12-04
AP3491A (en) 2015-12-31
AP2013007182A0 (en) 2013-10-31
SG194003A1 (en) 2013-11-29
MA35049B1 (fr) 2014-04-03
AU2012244859A1 (en) 2013-10-31
US20140120087A1 (en) 2014-05-01
PT2699575E (pt) 2015-07-29
JO3040B1 (ar) 2016-09-05
EP2699575B1 (en) 2015-03-25
DK2699575T3 (da) 2015-06-22
HK1190398A1 (zh) 2014-07-04
CN103608350A (zh) 2014-02-26
EA201301181A1 (ru) 2014-08-29
MX348783B (es) 2017-06-28
KR20140025470A (ko) 2014-03-04
DOP2013000244A (es) 2014-03-16
JP2014511887A (ja) 2014-05-19
CO6801751A2 (es) 2013-11-29
HUE025496T2 (en) 2016-04-28
IL228704A0 (en) 2013-12-31
ES2539265T3 (es) 2015-06-29
EP2699575A1 (en) 2014-02-26
ME02143B (me) 2015-10-20
CN103608350B (zh) 2015-11-25
ZA201308707B (en) 2016-07-27
MY164939A (en) 2018-02-15
TWI558703B (zh) 2016-11-21
CL2013003044A1 (es) 2014-05-02
CY1116439T1 (el) 2017-02-08
PH12013502169A1 (en) 2014-01-13
AR086191A1 (es) 2013-11-27
EA023766B1 (ru) 2016-07-29
AU2012244859B2 (en) 2017-06-08
MX2013012289A (es) 2013-11-21
WO2012143329A1 (en) 2012-10-26
HRP20150517T1 (hr) 2015-06-19
SI2699575T1 (sl) 2015-10-30
PL2699575T3 (pl) 2015-08-31

Similar Documents

Publication Publication Date Title
DOP2014000133A (es) Triazolopiridinas sustituidas
DOP2013000244A (es) Triazolopiridinas
ECSP12011935A (es) Triazolopiridinas
ECSP12012338A (es) Triazolopiridinas sustituidas
CO2017001035A2 (es) “2-(morfolin-4-il)-1,7-naftiridinas sustituidas, composiciones y combinaciones farmacéuticas que las comprenden, y compuestos intermediarios
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
ECSP14013217A (es) 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk.
NI201500142A (es) Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos.
UY35040A (es) Pirrolopirimidinilamino-benzotiazolonas sustituidas
UY32153A (es) Inhibidores de piridomidinona de pi13ka(alfa) y mtor
CR20160016A (es) Pirazolpiridinas sustituidas
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
UY35602A (es) Compuestos nuevos para el tratamiento del cáncer
CL2011003123A1 (es) Compuestos derivados de ciclopentanamida sustituidos; composicion farmaceutica; proceso de obtencion; y uso en el tratamiento o la profilaxis de la diabetes, aterosclerosis, entre otras.
UY31903A (es) 7-sulfanilmetil-,7-silfinilmetil-y7-sulfonilmetilindoles sustituidos y el uso de los mismos
CL2011003355A1 (es) Compuestos derivados de alcoxi-carbonil-amino-alquinil-adenosina ; composición farmacéutica que los comprende; uso del compuesto en la preparación de un medicamento útil para tratar enfermedades autoinmunes, inflamatorias, alérgicas, infecciosas entre otras.
CU20130141A7 (es) Triazolopiridinas
CL2011001916A1 (es) Uso de ezatiostat o una sal de el para el tratamiento del sindrome mielodisplasico; composicion farmaceutica que comprende a dicho compuesto ademas de lenalidomida; combinacion farmaceutica; kit farmaceutico.